Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Celldex Therapeutics, Inc. - Common Stock
(NQ:
CLDX
)
26.47
+0.80 (+3.12%)
Streaming Delayed Price
Updated: 12:52 PM EST, Jan 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Celldex Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Celldex Therapeutics Announces Upcoming Barzolvolimab Presentations at EAACI 2023
June 08, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Therapeutics to Present at Jefferies Healthcare Conference
June 02, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
4 Analysts Have This to Say About Celldex Therapeutics
↗
May 31, 2023
Via
Benzinga
Celldex Announces First Patient Dosed in Phase 1 Study of CDX-585 in Patients with Advanced Malignancies
May 31, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Therapeutics: Q1 Earnings Insights
↗
May 04, 2023
Via
Benzinga
Why Celldex Therapeutics Shares Are Trading Higher Today
↗
February 27, 2023
Via
Benzinga
Celldex Therapeutics Presents Positive Preclinical Data from TSLP/SCF Bispecific Antibody Program CDX-622 at IMMUNOLOGY2023™
May 15, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
A New Era In Regenerative Medicine? BioRestorative Therapies (NASDAQ: BRT) Reports Leading The Expansion Of The Adipose-Derived Stem Cell Therapy Market
↗
May 11, 2023
Brown Adipose-Derived Stem Cell (BADSC) therapy has emerged as a groundbreaking innovation in regenerative medicine, capturing the attention of scientists, clinicians and investors alike.
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
↗
May 09, 2023
Via
Benzinga
Celldex Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 04, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Therapeutics Earnings Perspective: Return On Capital Employed
↗
December 19, 2022
Via
Benzinga
Read How Cantor Views Celldex Therapeutics' Barzolvolimab Data
↗
July 05, 2022
Via
Benzinga
Celldex Therapeutics to Present at H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
March 29, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Reports Fourth Quarter and Year End 2022 Financial Results and Provides Corporate Update
February 28, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Union Pacific, Kosmos Energy, Fisker And Other Big Stocks Moving Higher On Monday
↗
February 27, 2023
U.S. stocks traded higher, with the Dow Jones gaining more than 300 points on Monday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at AAAAI 2023
February 26, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
February 16, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Therapeutics to Present at SVB Securities Global Biopharma Conference
February 15, 2023
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2023
February 03, 2023
Company to host webcast on Sunday, February 26 at 4:00 pm CT/5:00 pm ET
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
These '20 Stocks To Watch' Moved On Last Fed Rate Hike: How Will They React Today?
↗
February 01, 2023
The Federal Reserve's interest rate hike announcements have the potential to cause significant volatility in the stock market.
Via
Benzinga
BriaCell’s Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients
December 14, 2022
By Ernest Dela Aglanu, Benzinga
Via
News Direct
Topics
Death
BriaCell’s Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients
December 14, 2022
Small and big pharma companies such as Pfizer Inc. (NYSE: PFE), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Hologic Inc. (NASDAQ: HOLX) are ramping up efforts to help reduce or eliminate the growing...
Via
TheNewswire.com
Topics
Death
BriaCell's Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients
↗
December 13, 2022
Small and big pharma companies such as Pfizer Inc. (NYSE: PFE), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Hologic Inc. (NASDAQ: HOLX<
Via
Benzinga
Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Inducible Urticaria at Global Urticaria Forum 2022
December 06, 2022
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Therapeutics Announces Multiple Upcoming Presentations of Barzolvolimab Data at GA²LEN Global Urticaria Forum (GUF) 2022
December 02, 2022
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex to Participate in Upcoming November Investor Conferences
November 10, 2022
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 09, 2022
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Therapeutics Earnings Perspective: Return On Capital Employed
↗
August 31, 2022
Celldex Therapeutics (NASDAQ:CLDX) brought in sales totaling $163 thousand during Q2 according to data provided by Benzinga Pro. However, earnings decreased 56.2%, resulting in a loss of $36.00...
Via
Benzinga
HC Wainwright & Co. Maintains Buy Rating for Celldex Therapeutics: Here's What You Need To Know
↗
July 01, 2022
HC Wainwright & Co. has decided to maintain its Buy rating of Celldex Therapeutics (NASDAQ:CLDX) and raise its price target from $60.00 to $73.00. Shares of Celldex Therapeutics are trading down 14.91%...
Via
Benzinga
Accolade Shares Jump Around 29%, Here's 75 Biggest Movers From Friday
↗
July 05, 2022
Gainers Omeros Corporation (NASDAQ: OMER) jumped 68.7% to close at $4.64. Clovis Oncology, Inc. (NASDAQ: CLVS) gained 58.3% to settle at $2.85 on Friday.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
